Skip to main content

View full-text article in PMC

. 2024 Apr 5;15:1379538. doi: 10.3389/fimmu.2024.1379538

Table 5.

Meta-analysis showing efficacy of symptomatic treatment in MS.

Symptoms	Pharmacological treatment
Impaired gait	Fampridine (220)^* (221),^* (222),^* (223),
Spasticity	Cannabinoids (224)^* (225),^* (226), ^*
	Botulinum toxin (224)^*
	Nabiximols (227)^*
Pain	Cannabinoids (225)^*
Bladder dysfunction	Cannabinoids (225)^*
Bladder dysfunction	Desmopressin (228)^*
Fatigue	Amantadine (229) (230),^*
Cognitive dysfunction	Fampridine (220)^* (231),^¥
Finger dexterity	Fampridine (220)^*
Tremor/ataxia	Botulinum toxin (232)^* (233),^*

*Significantly higher efficacy compared to placebo in RCT; ^¥Only when assessed with the symbol digit modalities test (SDMT).